Research and Development Day to be held on December 10 at 1 pm. EXEL).com/events/event-details/exelixis-2025-rd-day-building-next-generation-oncology-franchises’ target= ‘_blank’; rel=’nofollow’>Webcast Link
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis’s Oncology Potential: A Buy Rating Amid Evolving mCRC Treatment Landscape and Unmet Needs
- Exelixis director buys $1.2M in common stock
- Exelixis initiated with a Peer Perform at Wolfe Research
- Exelixis Announces Leadership Transition with New General Counsel
- Exelixis price target raised to $45 from $44 at Morgan Stanley